ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2484

Immunogenicity Of TNFα Blockers In Patients With Psoriatic Arthritis

Michael Zisapel Zisapel1, Noa Madar-Balakirsi2, Hagit Padova3, Irena Wigler4, Daphna Paran5, Uri Arad4, Dan Caspi6 and Ori Elkayam7, 1Rheumatology, Tel Aviv Medical Centet, Tel Aviv, Israel, 2Rheumatology, Tel Aviv Medical Center, Tel Aviv, Israel, 3Rheumatology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, 4Department of Rheumatology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, 5Rheumatology, Tel Aviv Sourasky Medical Ctr, Tel-Aviv university, Tel Aviv, Israel, 6Rheumatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, 7Rheumatology, Tel-Aviv Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel- Aviv, Israel

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Adalimumab, Biologic agents, etanercept, infliximab and psoriatic arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment III

Session Type: Abstract Submissions (ACR)

Background/Purpose:

TNFα blockers have been shown to produce immunogenecity in patients with rheumatoid arthritis, spondyloarthrritis and inflammatory bowel diseases. Data on the induction of anti-drug antibodies against TNF alpha blockers in psoriatic arthritis is scarce. The purpose of this study was to assess the prevalence of anti-drug antibodies (ADA) against infliximab , adalimumab and etanercept in a cohort of patients with psoriatic arthritis (PsA).

Methods:

Patients with PsA treated for at least 3 months with adalimumab (n=48), infliximab (n=24) and etanercept ( n=21) participated in this study. Clinical activity was assessed using the DAS 28, physician and patient global assessment using a VAS of 100 mm, psoriasis assessement of severity score (PASI) , BASDAI, ESR and CRP.

Results:

ADA were  detected in 26 (55%) patients on adalimumab,  5 (28%)  on infliximab and none of the patients on etanercept. A significant correlation was found between the presence of ADA and drug levels of adalimumab and infliximab. A significant correlation was found between drug levels of adalimumab and global physician and patient assessment, and the PASI. In patients treated with infliximab, ADA was associated with higher DAS and PASI, Twenty-six % of the patients were concomitantly treated with methotrexate (MTX). A significant correlation  between the use of MTX and the absence of ADA was demonstrated in patients treated with infliximab and adalimumab.

Conclusion:

A substantial proportion of patients with PsA develop anti drug antibodies to adalimumab and infliximab. The use of MTX seems to lower immunogenecity. The presence of ADA correlated with drug levels and several parameters of disease activity.


Disclosure:

M. Z. Zisapel,
None;

N. Madar-Balakirsi,
None;

H. Padova,
None;

I. Wigler,
None;

D. Paran,
None;

U. Arad,
None;

D. Caspi,
None;

O. Elkayam,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/immunogenicity-of-tnf%ce%b1-blockers-in-patients-with-psoriatic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology